For women with a specific type of breast cancer known as HER2-positive (HER2+), any residual (leftover) disease after primary ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

The optimal approach to treatment in the post-CDK4/6 inhibitor setting remains undefined, but multiple strategies have ...

So in summary, HER2CLIMB-05 was a positive study. It showed that adding tucatinib for both HR-positive as well as HR-negative ...

What Is Metastatic HER2-Positive Breast Cancer? HER2-positive breast cancer happens when the cancer cells have higher than normal level of a protein called human epidermal growth factor receptor 2 ...

There has been an explosion of newer HER2-directed therapies, including monoclonal antibodies, novel antibody-drug conjugates ...

Trastuzumab deruxtecan continues to demonstrate superior safety and efficacy compared with trastuzumab emtansine in patients with high-risk, HER2-positive early breast cancer who have residual ...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer ...

AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved by the US FDA to treat adult ...

Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the FDA. Enhertu, a HER2-directed antibody-drug conjugate, inhibits tumor ...

Human epidermal growth factor receptor-2 (HER2) and neu are the human and rodent homologues of an oncogenic growth factor receptor that were identified and named independently in the early 1980s from ...